Mucosal Vaccines

Most infectious agents enter the body at mucosal surfaces and therefore mucosal immune responses function as a first line of defence. Protective mucosal immune responses are most effectively induced by mucosal immunization through oral, nasal, rectal or vaginal routes, but the vast majority of vaccines in use today are administered by injection. Immunisation involves the delivery of antigens to the mucosal immune system (dispersed or organised into units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in the oropharangeal cavity). The antigen delivery systems may comprise a simple buffer solution with/without adjuvants or an advanced particulate formulation, such as liposomes or nanoparticles. The most commonly evaluated route for mucosal antigen delivery is oral, but other routes have also been explored.

Mucosal tissues (e.g. nasal, oral, ocular, rectal, vaginal) cover a large surface of the body. Since many infections are initiated at mucosal sites, it is critical to develop strategies for neutralising the infectious agent at these surfaces. Mucosal vaccination involves the administration of vaccines at one or more mucosal sites leading to induction of immune responses at the mucosal site of administration, other mucosal sites, and/or systemically.

  • Edible Vaccines
  • Common vaccinations given by mucosal route
  • Mucosal Vaccines Delivery
  • Challenges in mucosal vaccine design
  • Mucosal vaccines development

Related Conference of Mucosal Vaccines

September 18-19, 2017

20th Global Summit & Expo on Vaccines, Immunization & B2B

(Global B2B Meetings in 1 Event) Houston, Texas USA
October 05-07, 2017

World Vaccines and Immunization Congress

Osaka, Japan
October 30-31, 2017

19th International Vaccines & B2B Congress

Chicago, USA

Mucosal Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in